Mitochondrial apoptosis and BH3 mimetics

Haiming Dai, X. Wei Meng, Scott H. Kaufmann

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.

Original languageEnglish (US)
Article number2804
StatePublished - 2016


  • BAK activation
  • BAX activation
  • BCL-2 inhibitors
  • BH3 mimetics
  • venetoclax

ASJC Scopus subject areas

  • General Immunology and Microbiology
  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Mitochondrial apoptosis and BH3 mimetics'. Together they form a unique fingerprint.

Cite this